search
Back to results

A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients

Primary Purpose

Bronchial Asthma

Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
Keratinocyte Growth factor
Saline placebo
Sponsored by
University Hospital Southampton NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bronchial Asthma focused on measuring Moderate asthmatic, uncontrolled

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 - 60 years, either gender
  • Confirmed diagnosis of asthma for > 1 year as defined by BTS guidelines, requiring treatment with high dose inhaled corticosteroids +/- long acting β2 agonists, with persisting symptoms requiring use of short-acting beta agonist therapy >3x/week.
  • Never-smoker or ex-smoker, having stopped >1 year ago, with <10 pack year history.
  • Subject must understand the procedures of the study and agree to participation in the study by providing written informed consent
  • Subject considered fit enough to undergo lung function testing including provocation tests, and bronchoscopy.
  • Subject must not be participating in another clinical trial or have done so within the last 12 weeks.

Exclusion Criteria:

  • Patients requiring regular maintenance oral steroids for their asthma, or those who are adhering to symbicort SMART single inhaler regime.
  • Pregnancy (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test >5mIU/ml), an intention to become pregnant or breast-feeding (lactating).
  • Subjects with active lung disease other than asthma
  • Significant medical (cardiopulmonary, neurological, renal, endocrine, gastrointestinal, psychiatric, hepatic or haematological)co-morbidity which in the view of the investigator could impact on the interpretation of results or participation in the trial, or which is uncontrolled with standard treatment.
  • Current participation in another clinical trial or previous participation within the last 12 weeks.
  • Alcohol or active drug abuse.
  • Ongoing allergen desensitisation therapy
  • Regular use of sedatives, hypnotics, tranquilisers
  • Cancer or previous history of cancer
  • Inability to understand directions for dosing and study assessment.
  • Inability to be contacted in case of emergency.

Sites / Locations

  • Biomedical Research Unit (Respiratory)

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Study drug

Placebo

Arm Description

Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.

Saline will be used as a placebo comparator

Outcomes

Primary Outcome Measures

Change in PD15 Mannitol
A standard bronchoprovocation test, the mannitol test, will be used to assess airway hyperreactivity (measured as the dose required to drop FEV1 (forced expiratory volume in 1 second) by 15%, PD15)

Secondary Outcome Measures

Change in PC20 Metacholine
A standard bronchoprovocation test, metacholine challenge, will be used to assess airway hyperreactivity (by measuring the concentration needed to drop FEV1 by 20%, PC20)
Change in asthma symptoms
Symptoms will be assessed using standardised questionnaires, Asthma control questionnaire (ACQ) and Asthma Quality of Life questionnaire (AQLQ)
Short acting beta-agonist use/PEFR variability
A diary card will be used throughout the study for participants to record beta-agonist use and morning/evening peak expiratory flow rates (PEFR), from the latter PEFR variability will be calculated
Adverse event reporting
Adverse events will be recorded if they occur
Epithelial integrity/activation
Bronchial biopsies, brush specimens and lavage fluid before and after intervention will be analysed to determine markers of activation, inflammation and epithelial integrity
Epithelial proliferation
Bronchial biopsy specimens will be analysed for markers of proliferation e.g. Ki67 before and after treatment
Exhaled nitric Oxide
Exhaled nitric oxide, as a surrogate marker of eosinophilic inflammation, will be measured before/during and after intervention

Full Information

First Posted
June 24, 2011
Last Updated
October 12, 2016
Sponsor
University Hospital Southampton NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT01386151
Brief Title
A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients
Official Title
Safety and Efficacy of Parenteral KGF in Moderate Asthmatic Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Southampton NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will look at the permeability, or 'leakiness' of the airway epithelium (the inner lining of the lung) in asthmatic patients. Increased leakiness of this lining has been shown in asthmatic patients by other studies, not only in the lung but also possibly in the gut, perhaps reflecting a widespread defect. This leakiness may underline the interaction between the environment and a person's genetic make up, and may contribute to why some people get asthma, and how severe it is. Increased leakiness may allow increased exposure to inhaled allergic substances, helping to perpetuate the inflammation in the lungs that is a hallmark of asthma. Specifically, this study will attempt to modify and reduce this permeability through the use of a substance called 'keratinocyte growth factor', or 'kgf'. KGF is a naturally occuring human protein, which is involved in stimulating the growth of cells lining the layers of the skin and gut, helping to repair damage and maintain their structure. It has been manufactured in a laboratory as the commercial compound 'Palifermin', which has already been used in humans to reduce damage to the lining of the mouth after chemotherapy. The study will see if Palifermin can similarly improve the lining of the lung in asthma patients and improve their symptoms. To date no treatments have been used in this area in asthma, and if successful the study will open up a whole new area of therapy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchial Asthma
Keywords
Moderate asthmatic, uncontrolled

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study drug
Arm Type
Active Comparator
Arm Description
Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Saline will be used as a placebo comparator
Intervention Type
Drug
Intervention Name(s)
Keratinocyte Growth factor
Other Intervention Name(s)
Palifermin, rhKGF, Kepivance
Intervention Description
KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
Intervention Type
Drug
Intervention Name(s)
Saline placebo
Intervention Description
Normal (0.9%) saline will be used as a placebo.
Primary Outcome Measure Information:
Title
Change in PD15 Mannitol
Description
A standard bronchoprovocation test, the mannitol test, will be used to assess airway hyperreactivity (measured as the dose required to drop FEV1 (forced expiratory volume in 1 second) by 15%, PD15)
Time Frame
Baseline (7 days prior to drug), during drug administration period (3 days after first dose of drug), and short/intermediate term post drug period (3, 6 and 24 days after second drug administration)
Secondary Outcome Measure Information:
Title
Change in PC20 Metacholine
Description
A standard bronchoprovocation test, metacholine challenge, will be used to assess airway hyperreactivity (by measuring the concentration needed to drop FEV1 by 20%, PC20)
Time Frame
Baseline (6 days prior to drug) and short/intermediate term post drug period (7 and 25 days after second drug administration)
Title
Change in asthma symptoms
Description
Symptoms will be assessed using standardised questionnaires, Asthma control questionnaire (ACQ) and Asthma Quality of Life questionnaire (AQLQ)
Time Frame
ACQ is measured weekly during study. AQLQ is measured at baseline screening visit, and on day 35 (35 days post first administration of drug).
Title
Short acting beta-agonist use/PEFR variability
Description
A diary card will be used throughout the study for participants to record beta-agonist use and morning/evening peak expiratory flow rates (PEFR), from the latter PEFR variability will be calculated
Time Frame
Throughout study
Title
Adverse event reporting
Description
Adverse events will be recorded if they occur
Time Frame
Throughout study
Title
Epithelial integrity/activation
Description
Bronchial biopsies, brush specimens and lavage fluid before and after intervention will be analysed to determine markers of activation, inflammation and epithelial integrity
Time Frame
Specimens are taken at 2 bronchoscopies, the first before the drug (4 days prior to the first drug administration) and the second after the drug (21 days after the first drug administration)
Title
Epithelial proliferation
Description
Bronchial biopsy specimens will be analysed for markers of proliferation e.g. Ki67 before and after treatment
Time Frame
Specimens are taken at 2 bronchoscopies, the first before the drug (4 days prior to the first drug administration) and the second after the drug (21 days after the first drug administration)
Title
Exhaled nitric Oxide
Description
Exhaled nitric oxide, as a surrogate marker of eosinophilic inflammation, will be measured before/during and after intervention
Time Frame
This is measured on the same days as PD15 mannitol, with an additional baseline measurement at the screening visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 - 60 years, either gender Confirmed diagnosis of asthma for > 1 year as defined by BTS guidelines, requiring treatment with high dose inhaled corticosteroids +/- long acting β2 agonists, with persisting symptoms requiring use of short-acting beta agonist therapy >3x/week. Never-smoker or ex-smoker, having stopped >1 year ago, with <10 pack year history. Subject must understand the procedures of the study and agree to participation in the study by providing written informed consent Subject considered fit enough to undergo lung function testing including provocation tests, and bronchoscopy. Subject must not be participating in another clinical trial or have done so within the last 12 weeks. Exclusion Criteria: Patients requiring regular maintenance oral steroids for their asthma, or those who are adhering to symbicort SMART single inhaler regime. Pregnancy (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test >5mIU/ml), an intention to become pregnant or breast-feeding (lactating). Subjects with active lung disease other than asthma Significant medical (cardiopulmonary, neurological, renal, endocrine, gastrointestinal, psychiatric, hepatic or haematological)co-morbidity which in the view of the investigator could impact on the interpretation of results or participation in the trial, or which is uncontrolled with standard treatment. Current participation in another clinical trial or previous participation within the last 12 weeks. Alcohol or active drug abuse. Ongoing allergen desensitisation therapy Regular use of sedatives, hypnotics, tranquilisers Cancer or previous history of cancer Inability to understand directions for dosing and study assessment. Inability to be contacted in case of emergency.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter H Howarth, BSc, MBBS
Organizational Affiliation
Reader in Medicine and Honorary Consultant Physician, Southampton General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Biomedical Research Unit (Respiratory)
City
Southampton
State/Province
Hampshire
ZIP/Postal Code
SO16 6YD
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients

We'll reach out to this number within 24 hrs